Inhibikase Therapeutics (IKT) Change in Receivables (2021 - 2023)
Inhibikase Therapeutics (IKT) posted quarterly Change in Receivables of -$79602.0 for Q3 2023, down 1191.93% year-over-year from $7290.0 in Q3 2022, and down 627.76% quarter-over-quarter from $15083.0 in Q2 2023.
Powered by 
Analysis
Inhibikase Therapeutics (IKT) Change in Receivables (2021 - 2023) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Change in Receivables for 3 consecutive years, with -$79602.0 the latest figure, recorded in Q3 2023.
- In Q3 2023, Change in Receivables fell 1191.93% year-over-year to -$79602.0; the TTM figure through Jun 2024 stood at -$79602.0 (down 143.45% YoY), while the FY2023 annual figure was -$39881.0, down 200.0% from the prior year.
- Change in Receivables fell to -$79602.0 in Q3 2023 per IKT's latest filing, from $15083.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $332774.0 in Q1 2021 and bottomed at -$369099.0 in Q3 2021.
- Historically, Change in Receivables has averaged $10012.8 across 3 years, with a median of $7290.0 in 2022.
- Annual changes were most pronounced in 2022 — Change in Receivables surged 226.87% — and 2023, when it tumbled 1191.93%.
- Inhibikase Therapeutics' Change in Receivables stood at -$107341.0 in 2021, then soared by 226.87% to $136180.0 in 2022, then slumped by 158.45% to -$79602.0 in 2023.
- Business Quant data shows IKT's Change in Receivables at -$79602.0 in Q3 2023, $15083.0 in Q2 2023, and $24638.0 in Q1 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -53.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 117.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 31.60 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Inhibikase Therapeutics | 435.56 Mn | 276.54 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2023 | -79,602.00 |
| Jun 30, 2023 | 15,083.00 |
| Mar 31, 2023 | 24,638.00 |
| Dec 31, 2022 | 136,180.00 |
| Sep 30, 2022 | 7,290.00 |
| Jun 30, 2022 | -41,424.00 |
| Mar 31, 2022 | -62,165.00 |
| Dec 31, 2021 | -107,341.00 |
| Sep 30, 2021 | -369,099.00 |
| Jun 30, 2021 | 253,807.00 |
| Mar 31, 2021 | 332,774.00 |